Indeed, suppression of JAK1/2 signalling with Baricitinib, in SARS‐CoV‐2‐infected macaques, significantly reduced macrophage recruitment and inflammatory signatures and preliminary data support its use in COVID‐19 (Bronte et al, 2020). This evidence concerns the gene JAK1 and COVID-19.